BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
BioArctic has dosed the first subject with the monoclonal antibody, exidavnemab, in the Phase IIa EXIST to treat Parkinson’s disease.
There is growing evidence that immune-positron emission tomography (immuno-PET) can provide a real-time quantitative readout ...
The new Marie Skłodowska-Curie Doctoral Network AIPD is dedicated to investigating artificial intelligence methods to combat Parkinson's disease. It ...
SOUTH SAN FRANCISCO, CA, USA I 05, 2024 I Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical ...
STOCKHOLM, Sweden I 5, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab ...
The 5-a-side match, which was held at the Eagle Club, Surulere, Lagos last weekend was in collaboration with Parkinson’s ...
A decline in motor skills is a hallmark of Parkinson's disease, regularly taking the form of slowness, rigidity, and tremors.
An Akron police officer shot and killed a 15-year-old boy who was carrying a gun with an extended magazine, according to body ...
Dan Teleman, CEO of Pharma Two B, added, “These data provide further support for P2B001 as a first-line, once-daily combination pill treatment for people with early PD that requires no titration.